gastric emptying glp-1 Interleukin-6 Delays in Humans with Direct Effects on Glycemic Control GLP-1 Receptor Agonists in Gastrointestinal

Trends & Treatment Insights for 2025 Real-world data show rapid adoption in type 2 diabetes care: between early 2022 and mid-2024, roughly 1 in 5 type 2 diabetes patients were on GLP-1 therapy

They found that a stable GLP-1-estradiol conjugate caused greater weight loss in obese male mice than either GLP-1 controls or labile GLP-1-estradiol conjugates

Eighty percent of the AIA-positive patients on TOUJEO with antibody test at baseline remained AIA positive at month 6

Request referral to appropriate specialists if needed Liver assessment : Ensure proper diagnosis through blood tests, FIB-4 calculation, and if indicated, imaging (ultrasound or FibroScan) or ELF testing Specialist review : Hepatology or endocrinology input may be needed to assess suitability Clinical trials : Some patients may be eligible for research studies examining GLP-1 agonists in NAFLD/NASH Patients should be aware that even when prescribed, GLP-1 agonists require ongoing monitoring, lifestyle modification remains essential, and treatment should be reviewed regularly to assess response and tolerability

For obesity alone, coverage follows the same optional state rules as Wegovy 13 states cover it as of early 2026

Your doctor will help you figure this out by looking at your progress, goals, and lifestyle